Myriad Genetics, Inc. ( MYGN) - Key Metrics
MYGN Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q1 | ? | ? | ? | ? |
| 2025Q4 | $2.25 | -$0.08 | $0.11 | $0.11 |
| 2025Q3 | $2.21 | -$0.29 | $0.23 | $0.20 |
| 2025Q2 | $2.30 | -$3.57 | -$0.15 | -$0.22 |
| 2025Q1 | $2.14 | $0 | -$0.18 | -$0.27 |
MYGN Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q1 | ? | ? |
| 2025Q4 | ? | -18.16 |
| 2025Q3 | ? | -6.14 |
| 2025Q2 | ? | -0.37 |
| 2025Q1 | ? | -2026.79 |
MYGN Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q1 | -3.72% | ? |
| 2025Q4 | 1.85% | ? |
| 2025Q3 | 2.72% | ? |
| 2025Q2 | -4.17% | ? |
| 2025Q1 | -3.03% | ? |
MYGN
Price: $4.57
52 week price:
Payout Ratio Range:
Earnings Per Share: -4.31 USD
Exchange: NMS
Sector: Healthcare
Industry: Diagnostics & Research
Country: United States
Volume: 315100
Ebitda: 17.5 millionMarket Capitalization: 397.6 million